The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis

@inproceedings{Patterson2016TheAD,
  title={The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis},
  author={Stephen H Patterson and Susan Wyllie and Suzanne Norval and Laste Stojanovski and Frederick R. C. Simeons and Jennifer L Auer and Maria Osuna-Cabello and Kevin D Read and Alan H. Fairlamb},
  booktitle={eLife},
  year={2016}
}
There is an urgent requirement for safe, oral and cost-effective drugs for the treatment of visceral leishmaniasis (VL). We report that delamanid (OPC-67683), an approved drug for multi-drug resistant tuberculosis, is a potent inhibitor of Leishmania donovani both in vitro and in vivo. Twice-daily oral dosing of delamanid at 30 mg kg(-1) for 5 days resulted in sterile cures in a mouse model of VL. Treatment with lower doses revealed a U-shaped (hormetic) dose-response curve with greater… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 11 times over the past 90 days. VIEW TWEETS
11 Citations
38 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Parasitology 130:31–42

  • S Gupta, V Yardley, +5 authors SK. Puri
  • Nitroimidazo-
  • 2015
Highly Influential
5 Excerpts

The mechanism of action of PA-824: Novel insights

  • HI Boshoff, CE. Barry
  • 2009
Highly Influential
7 Excerpts

Integrative Biology 2:215–218

  • M Matsumoto, H Hashizume, +5 authors M. Komatsu
  • 2006
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…